Stay updated with breaking news from Opgen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OpGen (NASDAQ:OPGN – Get Rating) had its target price decreased by Alliance Global Partners to $1.25 in a report released on Tuesday, The Fly reports. The firm currently has a “buy” rating on the medical research company’s stock. Alliance Global Partners’ price objective would indicate a potential upside of 78.57% from the company’s previous close. […]
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic...
Precigen (NASDAQ:PGEN – Get Rating)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Monday, TipRanks reports. They presently have a $10.00 target price on the biotechnology company’s stock. Separately, Zacks Investment Research upgraded Precigen from a “hold” rating to a “buy” rating and set a $1.50 […]
Total Q1 2022 revenues of $0.5 millionCash position of approximately $30.7 million to reach into Q1-2023 Management conference call scheduled for May 12, 2022, at 4:30 p.m. EDT ROCKVILLE, Md.,... | May 12, 2022
Precigen (NASDAQ:PGEN – Get Rating) is scheduled to issue its quarterly earnings data after the market closes on Monday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Precigen (NASDAQ:PGEN – Get Rating) last posted its earnings results on Tuesday, March 1st. The biotechnology company reported ($0.13) earnings […]